Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a leading annual conference of HIV research, clinical practice and progress.
The healthy volunteer trial, conducted by the collaborative nanomedicine research programme led by Pharmacologist Professor Andrew Owen and Materials Chemist Professor Steve Rannard, and in collaboration with the St Stephen’s AIDS Trust at the Chelsea & Westminster Hospital in London, examined the use of nanotechnology to improve the delivery of drugs to HIV patients. The results were from two trials which are the first to use orally dosed nanomedicine to enable HIV therapy optimisation.
Manipulation of matter
Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanomedicine is the application of nanotechnology to the prevention and treatment of disease in the human body. By developing smaller pills that are better for patients and less expensive to manufacture, this evolving discipline has the potential to dramatically change medical science and is already having an impact in a number of clinically used therapies and diagnostics worldwide.
Currently, the treatment of HIV requires daily oral dosing of HIV drugs, and chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to therapies.
Developing new therapies
Recent evaluation of HIV patient groups have shown a willingness to switch to nanomedicine alternatives if benefits can be shown. Research efforts by the Liverpool team have focused on the development of new oral therapies, using Solid Drug Nanoparticle (SDN) technology which can improve drug absorption into the body, reducing both the dose and the cost per dose and enabling existing healthcare budgets to treat more patients.
The trial results confirmed the potential for a 50 percent dose reduction while maintaining therapeutic exposure, using a novel approach to formulation of two drugs: efavirenz (EFV) and, lopinavir (LPV). EFV is the current WHO-recommended preferred regimen, with 70% of adult patients on first-line taking an EFV-based HIV treatment regimen in low- and middle-income countries.
The trial is connected to the University’s ongoing work as part of the multinational consortium OPTIMIZE, a global partnership working to accelerate access to simpler, safer and more affordable HIV treatment. Funded by the U.S. Agency for International Development, OPTIMIZE is led by the Wits Reproductive Health & HIV Institute in Johannesburg, South Africa, and includes the interdisciplinary Liverpool team, Columbia University, Mylan Laboratories and the Medicines Patent Pool (MPP). OPTIMIZE is supported by key partners including UNITAID and the South African Medical Research Council (SAMRC).
Benny Kottiri, USAID’s Office of HIV/AIDS Research Division Chief, said: “The potential applications for HIV treatment are incredibly promising. By aligning efforts, these integrated investments offer the potential to reduce the doses required to control the HIV virus even further, resulting in real benefits globally. This would enable the costs of therapy to be reduced which is particularly beneficial for resource-limited countries where the burden of disease is highest.”
To watch the presentation please click here.
[osd_subscribe categories=’HIV’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “HIV”‘]
Receive an email update when we add a new HIV article.
The Latest on: HIV
via Google News
The Latest on: HIV
- CDC updates its guidelines to encourage doctors to talk everyone who is sexually active about PrEP to prevent HIVon December 8, 2021 at 7:11 pm
The US Centers for Disease Control and Prevention is encouraging doctors to talk to all sexually active people about drugs that can help prevent HIV and to prescribe these drugs — known as pre ...
- Stanford Researchers Looking at Possible Link Between Omicron COVID Variant and HIVon December 8, 2021 at 6:26 pm
Medical researchers at Stanford may be unlocking key mysteries of how COVID-19 variants including Omicron came to be and why it's spreading so fast. They also may have found a key to slowing it down.
- 40 Years Positive From the AIDS Pandemic to an HIV Free Generationon December 8, 2021 at 6:19 pm
To honor 4 decades of battles against the HIV infection, the Galleria dei Frigoriferi Milanesi in Milan hosted from November 12 to December 5, 2021, the exhibition 40 years positive. From the AIDS ...
- What can 35-year-old stool samples tell scientists about HIV/AIDS?on December 8, 2021 at 5:00 pm
Men who contracted HIV in the early days of the HIV/AIDS pandemic harbored a greater relative abundance of pro-inflammatory vs. anti-inflammatory gut microbes before they became HIV-positive compared ...
- Democrats introduce bill to remove insurance barriers for HIV prevention medicineon December 8, 2021 at 12:00 pm
PrEP is 99% effective at preventing HIV transmission. This bill would stop insurance companies from requiring prior authorization to take ...
- CDC recommends dramatic expansion of HIV prevention medicationon December 8, 2021 at 10:09 am
While a cure for HIV has remained elusive, in recent years there have been great strides made in the prevention and management of HIV and AIDS, the disease the virus causes if left untreated. Now, the ...
- New Vaccine Ingredient May Battle COVID, Other Illnesses Including HIV: Studyon December 6, 2021 at 2:15 pm
A combination-style vaccine ingredient may help to make coronavirus vaccines and other inoculations more successful at staving off disease, according to a new study from researchers at the La Jolla ...
- Did HIV help Omicron evolve?on December 6, 2021 at 5:45 am
Here, we ask whether the high incidence of HIV in southern Africa might have provided the conditions needed for Omicron to evolve.
- Why addressing racism against Black women in health care is key to ending the US HIV epidemicon December 6, 2021 at 5:41 am
When Black patients are treated by Black doctors, they have better health outcomes – but fewer than 6 in 100 American doctors are Black. The Good Brigade/Digital Vision via Getty ImagesForty years ...
via Bing News